title: Tigecycline does not prolong corrected QT intervals in healthy subjects.
abstract: We evaluated the effect of tigecycline (50-mg and 200-mg doses) on corrected QT (QTc) intervals and assessed safety and tolerability in a randomized, placebo-controlled, four-period crossover study of 48 (44 male) healthy volunteers aged 22 to 53 years. Fed subjects received tigecycline (50 mg or 200 mg) or placebo in a blinded fashion or an open-label oral dose of moxifloxacin (400 mg) after 1 liter of intravenous fluid. Serial electrocardiograms were recorded before, and for 96 h after, dosing. Blood samples for tigecycline pharmacokinetics were collected after each recording. QTc intervals were corrected using Fridericia's correction (QTcF). Pharmacokinetic parameters were calculated using noncompartmental methods with potential relationships examined using linear mixed-effects modeling. Adverse events were recorded. The upper limits of the 90% confidence interval for the mean difference between both tigecycline doses and placebo for all time-matched QTcF interval changes from baseline were <5 ms. The tigecycline concentrations initially declined rapidly and then more slowly. In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h. Proportional or similar values were found for the group given 200 mg of tigecycline. Linear mixed-effects modeling failed to show an effect on QTcF values by tigecycline concentrations (P = 0.755). Tigecycline does not prolong the QTc interval in healthy subjects. This study has been registered at ClinicalTrials.gov under registration no. NCT01287793.
authors: Pfizer Inc, Collegeville, Pennsylvania, USA.
authors: Joan M
authors: JM
authors: Korth-Bradley
authors: Paul C
authors: PC
authors: McGovern
authors: Joanne
authors: J
authors: Salageanu
authors: Kyle
authors: K
authors: Matschke
authors: Anna
authors: A
authors: Plotka
authors: Sylvester
authors: S
authors: Pawlak
mesh_terms: D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D000078304:Tigecycline; D055815:Young Adult
chemical_list: D000078304:Tigecycline; D008911:Minocycline
references: Antimicrob Agents Chemother. 2013 Apr;57(4):1756-62
references: 23357775
references: Ann Pharmacother. 2007 Nov;41(11):1859-66
references: 17911203
references: Int J Infect Dis. 2005 Sep;9(5):251-61
references: 16099700
references: BMC Pulm Med. 2009 Sep 09;9:44
references: 19740418
references: Int J Antimicrob Agents. 2013 May;41(5):463-7
references: 23537581
references: Antimicrob Agents Chemother. 1999 Apr;43(4):738-44
references: 10103174
references: Antimicrob Agents Chemother. 2003 Mar;47(3):972-8
references: 12604529
references: Pharmacotherapy. 2007 Jun;27(6):835-44
references: 17542766
references: Antimicrob Agents Chemother. 2002 Aug;46(8):2595-601
references: 12121938
references: Antimicrob Agents Chemother. 2005 Apr;49(4):1656-9
references: 15793165
references: Diagn Microbiol Infect Dis. 2009 Oct;65(2):123-9
references: 19748422
references: Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36
references: 10744364
references: Antimicrob Agents Chemother. 2003 Jan;47(1):400-4
references: 12499224
references: Antimicrob Agents Chemother. 2005 Nov;49(11):4658-66
references: 16251309
references: Pharmazie. 2010 Sep;65(9):631-40
references: 21038838
references: Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61
references: 18990531
references: BMC Infect Dis. 2005 Oct 19;5:88
references: 16236177
references: J Clin Microbiol. 2009 May;47(5):1613
references: 19403778
references: Clin Pharmacol Ther. 2008 Oct;84(4):475-80
references: 19238652
references: Antimicrob Agents Chemother. 2005 Jan;49(1):220-9
references: 15616299
references: Fed Regist. 2005 Oct 20;70(202):61134-5
references: 16237860
references: Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67
references: 16080073